Genfit, a Phase 3 biotech developing therapies for NASH, filed on Wednesday with the SEC to raise up to $100 million in a US initial public offering.
The Loos, France-based company was founded in 1999 and booked $9 million in sales for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol GNFT. Genfit filed confidentially on November 16, 2018. SVB Leerink and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
